Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Non-Current Deffered Revenue: 2021-2025

Historic Non-Current Deffered Revenue for ARS Pharmaceuticals (SPRY) over the last 1 years, with Sep 2025 value amounting to $1.3 million.

  • ARS Pharmaceuticals' Non-Current Deffered Revenue was N/A to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year change of. This contributed to the annual value of $1.5 million for FY2024, which is N/A change from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Non-Current Deffered Revenue of $1.3 million as of Q3 2025, which was up 14.96% from $1.1 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Non-Current Deffered Revenue's 5-year high stood at $3.0 million during Q4 2021, with a 5-year trough of $1.1 million in Q2 2025.
  • Moreover, its 2-year median value for Non-Current Deffered Revenue was $1.3 million (2025), whereas its average is $1.3 million.
  • Data for ARS Pharmaceuticals' Non-Current Deffered Revenue shows a maximum YoY declined of 4.74% (in 2022) over the last 5 years.
  • Quarterly analysis of 4 years shows ARS Pharmaceuticals' Non-Current Deffered Revenue stood at $3.0 million in 2021, then fell by 4.74% to $2.9 million in 2022, then reached $1.5 million in 2024, then reached $1.3 million in 2025.
  • Its Non-Current Deffered Revenue was $1.3 million in Q3 2025, compared to $1.1 million in Q2 2025 and $1.3 million in Q1 2025.